| Protein FDR Confidence: Combined | Accession | Description | Exp. q-value: Combined | Sum PEP Score | Coverage [%] | # Peptides | # PSMs | # Unique Peptides | # AAs | MW [kDa] | calc. pI | # Peptides (by Search Engine): A2 Sequest HT (IgG 293) | # Peptides (by Search Engine): B2 Sequest HT (Sel1L 293) | # Peptides (by Search Engine): C2 Sequest HT (WT 293) | # Peptides (by Search Engine): D2 Sequest HT (HKO 293) | # PSMs (by Search Engine): A2 Sequest HT (IgG 293) | # PSMs (by Search Engine): B2 Sequest HT (Sel1L 293) | # PSMs (by Search Engine): C2 Sequest HT (WT 293) | # PSMs (by Search Engine): D2 Sequest HT (HKO 293) | Abundance: F1: Sample, IgG 293 | Abundance: F2: Sample, Sel1L 293 | Abundance: F3: Sample, WT 293 | Abundance: F4: Sample, HKO 293 | Abundances Count: F1: Sample, IgG 293 | Abundances Count: F2: Sample, Sel1L 293 | Abundances Count: F3: Sample, WT 293 | Abundances Count: F4: Sample, HKO 293 | Modifications | Biological Process | Cellular Component | Molecular Function | Pfam IDs | Entrez Gene ID | Ensembl Gene ID | Gene Symbol | Chromosome | Reactome Pathways | KEGG Pathways | # Razor Peptides |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| High | P42771 | Cyclin-dependent kinase inhibitor 2A OS=Homo sapiens OX=9606 GN=CDKN2A PE=1 SV=2 | 0 | 5.296 | 8 | 1 | 4 | 1 | 156 | 16.5 | 5.81 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 378554.125 | 537753 | 671486.125 | 406595.2188 | 1 | 1 | 1 | 1 | cell organization and biogenesis;metabolic process;regulation of biological process;response to stimulus | cytoplasm;cytosol;nucleus | catalytic activity;enzyme regulator activity;protein binding;RNA binding | "Pf12796, Pf13637, Pf13857" | 1029 | ENSG00000147889.17 | CDKN2A | 9 | Cyclin D associated events in G1; Oncogene Induced Senescence; Senescence-Associated Secretory Phenotype (SASP); Oxidative Stress Induced Senescence | Viral carcinogenesis; Pancreatic cancer; MicroRNAs in cancer; Chronic myeloid leukemia; Non-small cell lung cancer; Pathways in cancer; Glioma; Melanoma; HTLV-I infection; p53 signaling pathway; Bladder cancer; Cell cycle; Endocrine resistance; Platinum drug resistance | 0 |